EBS ▲ +4.8% - Emergent BioSolutions Inc. $EBS - Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) Emergent BioSolutions shares rose 4.8% after the company announced a contract modification worth approximately $24 million for its CYFENDUS anthrax vaccine. The additional funding for the FDA-approved vaccine expanded the company's existing government contract, providing a boost to revenue expectations for the therapeutic. 01-SEP-2026 07:55 AM ET